| Size | Price | Stock | Qty |
|---|---|---|---|
| 100g |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Biochemical reagent
|
|---|---|
| ln Vitro |
Used as sequestrant and general purpose food additive; Used in mirror production, Fehling's solution, crystal-controlled oscillators, and as saline cathartic; Used to make mirrors, in Fehling's solution, to control radio frequencies (and other applications of piezoelectric crystals), as chelator of metal ions (especially aluminum), and as cathartic.
|
| ln Vivo |
Polycystic ovary syndrome (PCOS) is the most common endocrine-related reproductive disorder in women of reproductive age, accompanied by both the impairment of female fecundity and a risk of metabolic disorders. PCOS is emphasized as a worldwide concern due to its unknown etiology and lack of specific medications. The current study aimed to evaluate the effects of L-tartaric acid, an abundantly occurring compound in fruits, on the histostereological and hormonal changes caused by PCOS. Forty adult Sprague Dawley rats were randomly divided into four groups including controls (no intervention), Tartaric acid (40mg/Kg/day from day 21 onwards for 39 days), PCOS (21 days letrozole and then normal saline orally for 39 days), and PCOS + Tartaric acid. After treatments, the ovarian histostereological analysis as well as the level of reproductive hormones including luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol, progesterone, and testosterone was measured. PCOS caused a significant decrease in the number of unilaminar, multilaminar, antral, and graafian follicles and increased follicular atresia (p-value < 0.001). Moreover, the weight and volume of ovarian tissue and related structures including cortex, medulla, and cysts increased significantly (p-value < 0.0001). However, corpus luteum volume was significantly decreased (p-value < 0.001). Although significant differences were found in some parameters with the control group (p-value < 0.05), the administration of tartaric acid restored the pathological effects of PCOS on the ovarian histostructure. Furthermore, tartaric acid improved the serum levels of LH, estradiol, progesterone, and testosterone (p-value < 0.05). The obtained findings may suggest tartaric acid as a novel strategy for PCOS management, although further studies are necessary [1].
|
| Toxicity/Toxicokinetics |
Non-human toxicity excerpt
A single intravenous injection of 400 mg/kg sodium potassium tartrate selectively damages the tubular epithelium of mice. Subcutaneous injection of 400 mg/kg in mice. The number of Paneth cells in the intestinal glands did not change significantly, but the granulation index decreased significantly on day 1 after treatment and returned to normal within 5 days. LEE HL et al; New Medicine Journal (SEE-CHOUAX) 17(3):345(1974) Drug Warnings Sodium salts (as a saline laxative) are contraindicated in patients with heart disease, edema or congestive heart failure, or those on a low-sodium diet. |
| References |
[1]. The Effects of L-Tartaric Acid on Ovarian Histostereological and Serum Hormonal Analysis in an Animal Model of Polycystic Ovary Syndrome. Reprod Sci. 2024 Nov;31(11):3583-3594.
|
| Additional Infomation |
L-Sodium potassium tartrate is an organic sodium-potassium salt of L-tartaric acid (molar ratio 1:1:1). It is a laxative. It is both a potassium salt and an organic sodium salt. It contains L-tartarate (2-).
Therapeutic Uses As a saline laxative, the usual adult dose is 5 to 10 grams. ...As a saline laxative.../It produces/watery excretion within 2-6 hours.../When taken on an empty stomach, it is most effective when combined with a large amount of fluid (at least 240 ml). Used to clear toxins in certain poisoning situations. Can be used to clear parasites after treatment with anthelmintic drugs and toxic anthelmintics. Drug Warnings Sodium salts (as a saline laxative) are contraindicated in patients with heart disease, edema, or congestive heart failure, and in those on a low-sodium diet. /Sodium Salt/ |
| Molecular Formula |
C4H4KNAO6
|
|---|---|
| Molecular Weight |
210.16
|
| Exact Mass |
281.996
|
| CAS # |
304-59-6
|
| PubChem CID |
9357
|
| Appearance |
White to off-white solid powder
|
| Density |
1.24
|
| Boiling Point |
100 °C
|
| Melting Point |
70~80℃
|
| Flash Point |
209.4ºC
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
12
|
| Complexity |
123
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
[C@@H]([C@H](C(=O)[O-])O)(C(=O)[O-])O.[Na+].[K+]
|
| InChi Key |
LJCNRYVRMXRIQR-OLXYHTOASA-L
|
| InChi Code |
InChI=1S/C4H6O6.K.Na/c5-1(3(7)8)2(6)4(9)10;;/h1-2,5-6H,(H,7,8)(H,9,10);;/q;2*+1/p-2/t1-,2-;;/m1../s1
|
| Chemical Name |
potassium;sodium;(2R,3R)-2,3-dihydroxybutanedioate
|
| Synonyms |
Rochelle salt; Seignette salt; 304-59-6; SODIUM POTASSIUM TARTRATE; Monopotassium monosodium tartrate; Sodium potassium L-tartrate; 147-79-5; Potassium sodium L(+)-tartrate;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: ≥ 100 mg/mL (475.83 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.7583 mL | 23.7914 mL | 47.5828 mL | |
| 5 mM | 0.9517 mL | 4.7583 mL | 9.5166 mL | |
| 10 mM | 0.4758 mL | 2.3791 mL | 4.7583 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA